Meeting
2024 ASCO Annual Meeting
A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma.
Authors
Nikhil I. Khushalani
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Nikhil I. Khushalani , Jayakumar Mani , Jocelyn Booth , Zoe Zhang , Mark Salvati , Israel Lowy , Matthew G. Fury , Karl Lewis , Garen Manvelian , Hussein A. Tawbi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT06246916
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS9611)
DOI
10.1200/JCO.2024.42.16_suppl.TPS9611
Abstract #
TPS9611
Poster Bd #
389a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma.
First Author: Ana Baramidze
Poster
2021 ASCO Annual Meeting
Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.
First Author: Omid Hamid
Poster
2023 ASCO Annual Meeting
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis.
First Author: Inderjit Mehmi
Poster
2023 ASCO Annual Meeting
A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.
First Author: Timothy J. Panella